ALS is a degenerative disorder of the nerves controlling movement (“motor neurons”). ALS causes muscles to become weak, which leads to paralysis. ALS is a condition that gradually damages the nerve cells in the brain and spinal cord.  Currently, there are no treatments to prevent, reverse, or stop the development of ALS.  However, there are some treatments that may slow down the progression of the disease. We are doing this research to find out if DNL343 can help with Amyotrophic Lateral Sclerosis (ALS).  We also want to find out if DNL343 is safe to take without causing too many side effects. THIS STUDY IS ENROLLING BY INVITATION ONLY

The goals of this study are:To describe the safety of 68Ga-R12961To describe preliminary imaging efficacy of 68Ga-R12961 in participants with advanced solid tumors.To compare 68Ga-R12961 positron emission tomography/computed tomography (PET/CT) scans with standard of care imaging in detecting tumor lesions among participants.To describe the image quality of 68Ga-R12961.To determine organ and whole-body dosimetry of 68Ga-R12961.To describe the pharmacokinetic (PK) profile of 68Ga-R12961.THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at Indiana University Simon Comprehensive Cancer Center (IUSCCC), please contact theIU Clinical Trials Office at Email: iutrials@iu.edu Phone: (317) 278-5632

The purpose of this 26 week study is is to evaluate the efficacy and safety of veverimer in treating adults with moderate-to-severe chronic kidney disease (CKD) and metabolic acidosis.THIS STUDY IS ENROLLING BY INVITATION ONLY

The purpose of this study is to test how well a new soft, wearable blood pressure device (Boppli™) measures blood pressure in babies compared to the standard blood pressure cuff used in the NICU. We will also look at whether cuff measurements may temporarily raise a baby’s blood pressure. Information from this study may help improve how high blood pressure is monitored in infants in the future.THIS STUDY IS ENROLLING BY INVITATION ONLY - Potential participants will be identified through review of hospitalized infants in the Simon Family Tower NICU by the neonatal nephrology and neonatology research teams based on documented eligibility criteria in the medical record. Once an eligible infant is identified, the primary clinical team will be consulted to confirm that it is appropriate to approach the family. A trained member of the study team will then contact the parent or guardian in person in the NICU or remotely via phone call to introduce the study and review participation. Clinicians will be identified through through documentation in Cerner or through the daily unit attending assignment sheet. RNs will be identified at the bedside at the time of communication about the study or through documentation in Cerner.